Diabetic retinopathy. by Drouilhet, J H
Diabetic Retinopathy is the leading cause
of new blindness in the 25 to 74 year age
group in the United States. The diabetic
patient has a twenty-five times greater risk of
developing blindness than the non-diabetic
patient. Only 50% of all patients with diabe
tes mellitus have actually been diagnosed)
The Community Epidemiologic Work Group
for Diabetes Mellitus in Hawaii showed a
prevalence of 25.2 per 1000 to 63 per 1000
persons based on self-reported data. The
State Blind Registry for 1992-1993 showed
diabetic retinopathy as the second leading
cause of all new blind cases (20.9%).2 Dia
betic retinopathy is a significant cause for
concern in Hawaii in regard to patient quality
of life and socioeconomic concerns.
Various factors have been studied in the
pathophysiology of Diabetic Retinopathy to
include aldose reductase, growth hormone,
blood rheology abnormalities, blood viscos
ity,’ vascular endothelial growth factor,3etc.
It is as yet not fully understood how much
each of these (or other unknown factors)
contributes to the retinal vascular disease
process.
Duration of diabetes mellitus is critical
relative to the Onset of retinopathy. Type I
diabetics usually have no retinopathy until
five years after diagnosis. By 15 years into
the disease 90% will have retinopathy. Type
II diabetics can present with retinopathy on
initial diagnosis. The recommendation for
dilated eye examination in the Type I dia
betic is yearly once the patient has had diabe
tes for five years. Type II diabetics should be
examined yearly from time of diagnosis)
Definite risk factors for diabetic retinopa
thy include duration of disease, poor glucose
control, hypertension, and renal disease.4As 87% of patients with
advanced retinopathy have nephropathy and/or neuropathy, patients
with nephropathy and/or neuropathy definitely need an ophthalmo
logic exam.5
Diabetic Retinopathy has two major classifications—Non-Prolif
erative Diabetic Retinopathy (NPDR) and Proliferative Diabetic
Retinopathy (PDR).’ In NPDR one sees retinal microaneurysms,
blot hemorrhages, cotton wool spots, intraretinal microvascular
abnormalities, and retinal edema (Fig I). Edema affecting the
macula causes loss of central (reading) vision. PDR is the more
advanced stage occurring when the retina starts to lose its blood
supply. The eye responds by growing new blood vessels on the optic
nerve or retina (Fig 2). These fragile new vessels bleed, filling the
vitreous cavity. Scar tissue accompanies the neovascularization and
can cause retinal detachment (Fig 3).
To combat Diabetic Retinopathy, surgical strategies were devel
oped in which Laser surgery treats macular edema and causes
atrophy of the neovascularization. Vitrectomy surgery removes
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dense vitreous hemorrhage and relieves traction 
retinal detachment from scarring. 
The Early Treatment Diabetic Retinopathy 
Study (ETDRS)6 demonstrated a 50% reduction 
in loss of vision with appropriate laser surgery 
for clinically significant macular edema (Fig 4 ). 
This study also showed that aspirin did not 
reduce progression of diabetic retinopathy nor 
increase the risk of vision loss from vitreous 
hemorrhage.7 The Diabetic Retinopathy Study 
showed a 50-60% reduction in vision loss for 
timely laser surgery in patients with Prolifera-
tive Diabetic Retinopathy (Fig 5). 8 The Diabetic 
Retinopathy Vitrectomy Study showed better 
visual result with early vitrectomy surgery in 
Type I Diabetics with nonclearing vitreous hem-
orrhage (Fig 6).9 
The Diabetes Control and Complications Trial 
(DCCT) showed delay in onset and slower pro-
gression of Diabetic Retinopathy, nephropathy, 
and neuropathy. There was a 50% reduction in 
amount of laser surgery for Diabetic Retinopa-
thy in tightly controlled diabetics. 10 
Diabetic Retinopathy is the major cause of 
new blindness in working Americans. The longer 
the duration of diabetes, the greater the risk of 
retinopathy. Excellent serum glucose, blood pres-
sure, and cholesterol controlll delay and de-
crease the severity of retinopathy. Timely laser 
surgery reduces vision loss by 50%. It is the 
responsibility of all physicians in partnership to 
diagnose and properly manage the diabetic pa-
tient. 
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